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Significance of this study
What is already known about this subject?
 ► We searched PubMed and MEDLINE for 
English language publications in humans up 
to October 2016 for randomised controlled 
trials (RCT), open and observational studies of 
Endocuff and Endocuff Vision. We identified 
four case series studies and four multicentre 
RCT using the original Endocuff. Findings from 
case series reported that Endocuff provided 
more stability during mucosectomy, improved 
Mean number of Adenomas detected per 
Procedure (MAP) and resulted in adenoma 
detection rates (ADR) of up to 44.7%. 
However, small, superficial, ‘scratch-like’ 
mucosal lesions were observed, especially 
in the ileocaecal region in 30% of patients. 
Two multicentre RCTs from Germany and one 
from the USA reported an ADR increase of 
14%, 85% and 16.6% with Endocuff-assisted 
colonoscopy. However, the largest multicentre 
RCT was a Dutch study of 1063 procedures, 
which reported no significant difference in 
ADR but a higher MAP with Endocuff-assisted 
colonoscopy. A single- centre trial of Endocuff 
Vision has recently reported no improvement 
in ADR, but this was a small study. No 
multicentre RCTs of the second-generation 
Endocuff Vision, as used in this trial, have 
been published.
What are the new findings?
 ► We present findings from the first multicentre 
RCT comparing Endocuff Vision-assisted 
colonoscopy with standard colonoscopy 
in patients attending for symptomatic, 
surveillance and Bowel Cancer Screening 
Programme colonoscopy. Thus, this is the first 
study to demonstrate improved ADR with 
Endocuff Vision.
AbSTrACT
Objective low adenoma detection rates (aDr) are 
linked to increased postcolonoscopy colorectal cancer 
rates and reduced cancer survival. Devices to enhance 
mucosal visualisation such as endocuff Vision (eV) may 
improve aDr. this multicentre randomised controlled trial 
compared aDr between eV-assisted colonoscopy (eac) 
and standard colonoscopy (Sc).
Design Patients referred because of symptoms, surveillance 
or following a positive faecal occult blood test (FOBt) as part 
of the Bowel cancer Screening Programme were recruited 
from seven hospitals. aDr, mean adenomas per procedure, 
size and location of adenomas, sessile serrated polyps, eV 
removal rate, caecal intubation rate, procedural time, patient 
experience, effect of eV on workload and adverse events 
were measured.
results 1772 patients (57% male, mean age 62 years) 
were recruited over 16 months with 45% recruited through 
screening. eac increased aDr globally from 36.2% to 
40.9% (P=0.02). the increase was driven by a 10.8% 
increase in FOBt-positive screening patients (50.9% Sc vs 
61.7% eac, P<0.001). eV patients had higher detection 
of mean adenomas per procedure, sessile serrated polyps, 
left-sided, diminutive, small adenomas and cancers (cancer 
4.1% vs 2.3%, P=0.02). eV removal rate was 4.1%. Median 
intubation was a minute quicker with eac (P=0.001), 
with no difference in caecal intubation rate or withdrawal 
time. eac was well tolerated but caused a minor increase 
in discomfort on anal intubation in patients undergoing 
colonoscopy with no or minimal sedation. there were no 
significant eV adverse events.
Conclusion eV significantly improved aDr in bowel 
cancer screening patients and should be used to improve 
colonoscopic detection.
Trial registration number nct 02552017, results; 
iSrctn 11821044, results.
InTrODuCTIOn
Adenoma detection rate (ADR) is the most important 
marker of colonoscopy quality.1 2 Low ADR 
correlates with higher postcolonoscopy colorectal 
cancer (PCCRC) rates and poorer outcomes.3–7 
Measures to improve ADR such as optimising 
bowel preparation, slower withdrawal time, use of 
antispasmodics, improved training, position change 
and new technologies to improve mucosal visualisa-
tion have been developed.8–13
Lesions located on the proximal side of colonic 
folds present a particular problem and established 
manoeuvres such as retroflexion may not be possible 
in much of the colon.12 13 Devices that attach to the 
tip of the scope have been created to flatten folds but 
have not been demonstrated to consistently improve 
ADR.14
Endocuff Vision (EV) (figure 1) is a polypropylene 
device mounted onto the distal tip of a colonoscope. 
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Figure 1 Endocuff Vision (personal photograph by author).
Figure 2 Endocuff (personal photograph by author).
Significance of this study
How might it impact on clinical practice in the foreseeable 
future?
 ► The results of the Accuracy of Detection using Endocuff 
Optimisation of Mucosal Abnormalities (ADENOMA) study 
demonstrate that Endocuff Vision is a safe device, which 
improves ADR in the faecal occult blood test positive 
screening population. It speeds up procedures and is 
generally well tolerated by patients.
It consists of a fixed portion and a row of eight soft projections, 
which fold backwards during insertion but are pulled forwards 
during withdrawal to hold back colonic folds. EV is a second-gener-
ation device replacing the original Endocuff which had two rows of 
shorter, firmer projections. The original Endocuff (figure 2) demon-
strated an improvement in ADR in some studies but this was not 
replicated in a large randomised controlled trial (RCT).15 16 The 
original Endocuff was reported to cause mucosal abrasions, there-
fore to minimise this and to further improve detection characteris-
tics the EV was created.17
METHODS
Study design
Patients were recruited at seven hospitals (one academic and six 
community) in England between November 2014 and February 
2016. Colonoscopists who perform colonoscopy on posi-
tive faecal occult blood (FOBt) patients as part of the English 
Bowel Cancer Screening Programme (BCSP) undergo additional 
accreditation and may not reflect typical colonoscopy practice.1 
Therefore, each site was limited to four BCSP colonoscopists. A 
maximum of 10 colonoscopists per site were allowed to partic-
ipate in the trial. A learning curve for EV has been reported18; 
therefore, all colonoscopists were required to perform a 
minimum of 20 cases with EV prior to study commencement 
and were trained by means of a presentation and video. Usual 
colonoscopy equipment as available in each site was used with 
no restrictions placed on type of equipment used. Left colon 
was defined as transverse colon, splenic flexure, descending 
colon, sigmoid and rectum. Right colon was defined as caecum, 
ascending colon and hepatic flexure. The study protocol has 
been published.19 The ADENOMA trial has been registered 
with  clinicaltrials. gov NCT 02552017, International Standard 
Randomised Controlled Trials Number ISRCTN 11821044 and 
UK Clinical Research Network 17 718.
Participants
Patients older than 18 years and referred for colonoscopy for 
clinical symptoms, as part of a postpolypectomy surveillance 
programme or with positive FOBt as part of BCSP, were invited.1 
Patients were excluded if there was a pre-endoscopy suspicion 
of large bowel obstruction; known colon cancer or polyposis 
syndromes; known colonic stricture; known severe diverticular 
segment; known active colitis; on anticoagulants which had not 
been stopped preprocedure (meaning polypectomy might not be 
undertaken); if pregnant or attending for a therapeutic procedure 
or assessment of a known lesion. Some invited patients were not 
able to be recruited for logistical reasons such as unavailability of 
a research nurse or last-minute procedure cancellation.
Removal of EV during colonoscopy was indicated where: 
acute angulation in a fixed sigmoid colon rendered scope inser-
tion more difficult; a new diagnosis of polyposis syndrome or 
active colitis was made; or a new stricture that might impede 
insertion was identified.
randomisation and masking
Stratified randomisation based on age, gender, hospital site and 
BCSP status was performed using a dynamic adaptive algo-
rithm created by the North Wales Organisation for Randomised 
Trials in Health Clinical Trials Unit.20 Randomisation was via a 
computerised internet-based platform. Patients, colonoscopists 
and research nurses were not blinded to randomisation arm, but 
all study analyses were conducted in a blinded fashion.
Outcomes
The primary aim was to ascertain if there was a difference in 
ADR between EV-assisted colonoscopy (EAC) and standard 
colonoscopy (SC).
The secondary aims were:
1. To ascertain if there was a difference in Mean number of 
Adenomas per Procedure (MAP) between EAC and SC.
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Table 1 Patients excluded from the study
reasons
no. of 
patients
Gender
AgeM (%) F (%) 
Not eligible 909 499 (55) 410 (45) 62 (range 17–98)
Declined to participate 749 347 (46) 402 (54) 63 (range 17–94)
Research team 
unavailable
253 124 (49) 129 (51) 61 (range 22–88)
Procedure cancelled 139 78 (56) 61 (44) 62 (range 18–88)
Did not attend 100 60 (60) 40 (40) 56 (range 22–85)
Randomisation system 
maintenance
6 4 (67) 2 (33) 67 (range 60–72)
2. To ascertain the distribution of polyps in the colon compar-
ing EAC and SC (including assessment of cancer detection).
3. To ascertain if there was a difference in the detection of 
sessile serrated polyps (SSP) between EAC and SC.
4. To establish the rate of cuff exchange (ie, how often the cuff 
had to be removed).
5. To demonstrate non-inferiority of caecal intubation rate 
and insertion time to caecum comparing EAC and SC.
6. To demonstrate non-inferiority in complete withdrawal 
time in procedures where no polyps were detected compar-
ing EAC and SC.
7. To demonstrate non-inferiority of patient experience when 
comparing EAC and SC.
8. To measure any difference in future colonoscopic work-
load due to increased ADR by generating follow-up sur-
veillance procedures based on national (British Society of 
Gastroenterology (BSG)) guidelines comparing EAC and SC 
groups.
9. To measure any difference in ADR between BCSP and 
non-BCSP colonoscopists comparing EAC and SC.
10. To compare the ADR of the first 20% of patients scoped 
by each colonoscopist with the last 20% of patients in each 
arm to identify any changes in ADR throughout the trial.
11. To compare the baseline ADR of each colonoscopist before 
trial recruitment with that colonoscopist’s ADR during the 
trial in SC cases. Baseline was calculated over a period of 6 
months pretrial.
Patients were followed up for 21 days and any adverse events 
(AE) and serious adverse events (SAE) were reported to the 
Data Monitoring Committee. The chair of the Data Monitoring 
Committee and two independent clinicians reviewed each case 
to determine if events were related to the trial. Patient comfort 
was assessed by a validated nurse assessment questionnaire and 
two patient questionnaires.21
Statistical analysis
The study was powered to demonstrate a difference in ADR 
between EAC and SC. In calculating the sample size, different 
ADRs were used for BCSP (FOBt positive) and non-BCSP 
patients. In BCSP, ADR is 45% and in non-BCSP it is 16%.1 22 
A 10% increase in BCSP and 5% increase in non-BCSP were 
considered clinically significant. The ratio of BCSP to non-BCSP 
participants was projected to be 20:80. ADR for all patients 
combined was predicted to be 21.8% and a 6% increase was 
deemed clinically significant. To demonstrate a 6% increase 
with a 5% significance level and 90% power using a one-sided 
test, 886 patients per group were required. While patients were 
randomised to EAC or SC based on BCSP or non-BCSP status, 
restrictions to ensure that recruitment was in the 20:80 ratio 
were not mandated.
A one-sided Χ2 test was used to compare the primary outcome 
between groups. Additionally, as a sensitivity analysis, logistic 
regression was used to re-examine group differences adjusting 
for stratification factors included in the randomisation process. 
MAP was a secondary outcome and was analysed using the 
Mann-Whitney U test due to the positively skewed distribu-
tion. Χ 2 test and Mann-Whitney U test were used to analyse 
secondary outcomes where the objective was to examine the 
superiority of EAC. Other secondary outcomes were examined 
on a non-inferiority basis. For continuous outcomes, one-sided 
97.5% CI for the mean difference between groups was calcu-
lated. For binary outcomes, a one-sided 97.5% CI for the differ-
ence in proportions was calculated. Non-inferiority was assumed 
when the bound of the CI did not cross the prespecified point 
of non-inferiority. All superiority analyses were performed on an 
intention-to-treat (ITT) basis. Per-protocol analyses were used 
for outcomes analysed on a non-inferiority basis and as a sensi-
tivity analyses for the primary outcome.
rESulTS
A total of 3928 patients were invited to participate in the trial; 
2156 patients were excluded as they were ineligible (42%), 
declined participation (35%) or could not be recruited for logis-
tical reasons (23%) (table 1). Patient characteristics of recruited 
and excluded patients were comparable.
A total of 1772 patients were recruited, and the trial flow chart 
is illustrated in figure 3. Forty-eight colonoscopists participated 
in the trial, of which 17 were BCSP colonoscopists. No patients 
were lost to follow-up. Fifty-seven per cent patients were male 
with mean age 62 years. Patient characteristics were comparable 
in both groups (table 2). Bowel preparation was of an equivalent 
standard in both groups.
ADR was significantly higher with EAC (40.9% vs 36.2%, 
P=0.02) when analysed on ITT (table 3). The odds of adenoma 
detection were 22% higher with EAC. This was consistent when 
analysed per protocol. Model-based sensitivity analysis demon-
strated a significant benefit of EAC in increasing ADR when 
adjusted by site, colonoscopist, indication for procedure and 
age. ADR improvement was driven by an increase in the BCSP 
subgroup with a 10.8% increase (61.7% with EAC vs 50.9% 
with SC, P<0.001) (table 4). There was a global rise in MAP 
for EAC (0.95 vs 0.75, P=0.02) that was driven by the BCSP 
subgroup (EAC 1.59 vs SC 1.20, P=0.004) (table 5).
Polyp detection was higher with EAC (54.1% vs 48%, 
P=0.005), again with the difference driven by BCSP. Left colon 
adenomas were significantly higher with EAC (26.1% vs 22.2%, 
P=0.03). Significant differences were demonstrated for patients 
with small (6–9 mm) and diminutive (≤5 mm) adenomas in favour 
of EAC.  Again, the BCSP subgroup showed a significant differ-
ence between EAC and SC, while the non-BCSP subgroup did 
not. There were no differences for large adenomas (10+ mm), 
nor for the detection of right-sided adenomas. SSP detection rate 
was higher in the EAC arm (2.3% vs 1.1%, P=0.03). In contrast 
to the other outcomes, SSP detection was significantly increased 
with EAC only in the non-BCSP subgroup.
A total of 56 colorectal cancers (CRC) were detected with 36 
patients in the EAC arm and 20 patients in the SC arm (4.1% vs 
2.3%, P=0.02) (table 6). The increase in CRC detection with 
EAC was in the BCSP subgroup (6.6% vs 3.7%, P=0.03). There 
was no significant difference in the non-BCSP subgroup. When 
cancers were further subdivided into those diagnosed based on 
endoscopic appearances (recorded as a cancer endoscopically and 
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Figure 3 Trial profile. EAC, EV-assisted colonoscopy; SC, standard colonoscopy. 
Table 2 Demographics and colonoscopy indication for all patients
SC (n=884)(%) EAC (n=888)(%)
Male 502 (56.8) 507 (57.1)
Female 382 (43.2) 381 (42.9)
Age—mean (SD) 62.1 (11.1) 61.7 (11.7)
Age <60 years 273 (30.9) 273 (30.7)
  60–73 years 515 (58.3) 514 (57.9)
  74+ years 96 (10.9) 101 (11.4)
Previous abdominal surgery 
  No 542 (61.3) 547 (61.6)
  Yes 342 (38.7) 341 (38.4)
Recruitment
  Non-BCSP patients 481 (54.4) 494 (55.6)
  BCSP patients 403 (45.6) 394 (44.4)
Indications for colonoscopy
  BCSP 282 (32.0) 274 (30.9)
  BCSP surveillance 88 (10.0) 89 (10.0)
  Colonoscopy conversion from 
bowel scope
32 (3.6) 31 (3.5)
  Symptomatic diagnostic 346 (39.1) 357 (40.2)
  Symptomatic surveillance 135 (15.3) 137 (15.4)
BCSP, Bowel Cancer Screening Programme; EAC, EV-assisted colonoscopy; SC, 
standard colonoscopy.
confirmed histologically) and polyp cancers (recorded as a polyp 
but later found to contain cancer at histological assessment), EAC 
increased the detection of endoscopically found cancers globally, 
but polyp cancers only in the BCSP subgroup. Characteristics of 
cancers were comparable in the two groups with the the most 
common site being the sigmoid colon (17 patients).
EV cuff removal rate was 4.1%. The most common reason 
for removal was angulation in a fixed sigmoid colon (52.8% 
of removals). Other reasons included new cancer diagnosis 
(19.4%), identification of colonic strictures (16.7%) and a new 
diagnosis of active colitis (2.8%). The rate of EV removal was 
similar in both subgroups (BCSP 3.8% vs non-BCSP 4.3%).
Caecal intubation rate was equivalent in both arms (table 7). 
Median insertion time to caecum was 8 min with EAC and 9 min 
with SC (P=0.001). There was no difference in withdrawal 
times for procedures without polyps. When asked specifically 
about discomfort on anal intubation, 8.6% patients found this 
more uncomfortable with EAC; however, for all other measures 
of comfort EAC was non-inferior to SC.
The use of hyoscine-n-butylbromide to relax the colon was 
more common with EAC (627 vs 568, P=0.002). This differ-
ence was greater in the non-BCSP subgroup. There were no 
differences between groups in the use of carbon dioxide versus 
air insufflation, use of position change or rectal retroflexion 
(table 8). EAC met the criteria for all non-inferiority measures 
for the use of sedation and analgesia (table 9).
The BSG surveillance guidelines were used to determine whether 
patients with adenomas were low (requiring no surveillance or 
colonoscopy in 5 years), intermediate (colonoscopy in 3 years) or 
high (colonoscopy in 1 year) risk.23 In the EAC arm, 15.5% were 
intermediate or high risk requiring surveillance compared with 
13% (P=0.03) in the SC arm (table 10).
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Table 3 Primary outcome for all patients
Analysis Adenoma detection SC n (%) EAC n (%) % Difference (one-sided 95% CI) One-sided P value
Intention to treat No adenoma 564 (63.8%) 525 (59.1%)
1+ adenomas 320 (36.2%) 363 (40.9%) 4.7% (0.9% to ∞) 0.02
PP 1* No adenoma 564 (63.8%) 525 (59.2%)
1+ adenomas 320 (36.2%) 362 (40.8%) 4.6% (0.8% to ∞) 0.02
PP 2† No adenoma 564 (63.8%) 498 (58.5%)
1+ adenomas 320 (36.2%) 353 (41.5%) 5.3% (1.4% to ∞) 0.01
*Omitting patients where Endocuff was not used.
†Omitting patients where Endocuff was not used and where Endocuff was removed.
EAC, EV-assisted colonoscopy; PP, per- protocol; SC,  standard colonoscopy. 
Table 4 Primary outcome for subgroups
Subgroup
SC EAC
% Difference (one-sided 95% CI) One-sided P valuen % ADr n % ADr
BCSP patients 403 50.9% 394 61.7 10.8% (5.1% to ∞) 0.001
Non-BCSP patients
  All 481 23.9% 494 24.3 0.4% (-4.1% to ∞) 0.44
  Non-BCSP colonoscopists 411 24.1% 425 23.8 −0.3% (-5.2% to ∞) 0.54
  BCSP colonoscopists 70 22.9% 69 27.5 4.7% (-7.4% to ∞) 0.26
ADR, adenoma detection rate; BCSP, Bowel Cancer Screening Programme; EAC, EV-assisted colonoscopy; SC, standard colonoscopy.
There were no differences in individual colonoscopists’ ADR 
between the first 20% and last 20% of procedures. In addition, 
when comparing pretrial ADR of all colonoscopists with trial 
ADR in the SC arm to help assess for the Hawthorn effect, there 
was only an increase in ADR for one out of the 48 colonoscopists 
with their ADR increasing by 23.3% (P<0.01). There was no 
difference in experience of colonoscopists between the two arms 
of the study. Olympus colonoscopes were used in 1760/1772 
cases and there was no difference in type of scope found between 
both study arms.
There were 23 AEs of which 11 were in the EAC arm. AEs 
were reported to the Data Monitoring Committee and analysed 
by two independent clinicians. No AEs were judged to be related 
to use of EV.
DISCuSSIOn
This multicentre RCT demonstrated that EV significantly 
improved ADR, MAP and cancer detection, driven by improve-
ment in bowel cancer screening patients. ADR is widely accepted 
as the most important contemporaneous marker of colonoscopy 
quality with low ADR strongly linked to higher PCCRC rates. 
These results are highly significant with major potential clin-
ical impact.3 24 In a Polish study, colonoscopists with an ADR 
of <20% had an HR for PCCRC 10 times higher than colo-
noscopists with an ADR of >20% (ADR ≥20%, absolute risk 
0.011% vs ADR <20% absolute risk 0.115%).3 An American 
study found an inverse relationship between ADR and risk of 
PCCRC, advanced-stage PCCRC and fatal PCCRC.4 A 1% 
increase in ADR was associated with a 3% reduction in PCCRC 
and a 5% reduction in fatal PCCRC.4 If results of the current 
trial mirrored this study, EV could reduce the risk of PCCRC by 
14% and fatal PCCRC by 24%.
The increase in ADR, MAP and cancer in the EAC arm was 
driven by BCSP patients. These patients were FOBt positive 
and consequently had high rates of neoplastic pathology. These 
results suggest that EV improves visualisation and ADR in a 
population where neoplastic pathology is more common. ADR 
also relies on colonoscopists being observant, understanding 
pathology and rigorous in removing lesions. BCSP colonosco-
pists are accredited to a minimum standard in these areas and 
it may be that EV works most effectively when used by colo-
noscopists with these skills. ADR in both subgroups was higher 
than predicted but mirrors recent improvements in English 
data. These higher rates might also represent improved perfor-
mance in a trial setting; however, most colonoscopists did not 
significantly improve their ADR above pretrial levels in the SC 
arm making this explanation unlikely. While this trial stratified 
for the BCSP subgroup in both arms, it did not mandate the 
proportion of overall patients recruited as BCSP and non-BCSP 
meaning that recruitment differed from the anticipated 20/80 
ratio. Over-recruitment of BCSP patients most likely occurred 
because of the optimal research environment found in BCSP, 
with research motivated clinicians and nurses, leading to high 
levels of recruitment in this setting.
Increased detection of adenomas with EV was in the left colon 
where colonic folds are most prominent. EV assists detection 
by holding back and everting colonic folds and allowing them 
to slowly revert to their anatomical position, thereby improving 
mucosal visualisation. Improved detection was not mirrored 
in the right colon where the colon is generally straighter with 
less folds. Right-sided cancers and the failure of screening 
programmes to protect against them are becoming an increasing 
problem and it is unlikely EV would address this issue. As might 
be expected, EV improved detection of small and diminutive 
polyps but not larger polyps; however, somewhat surprisingly 
cancer detection was improved. While this was not expected, 
previous studies have demonstrated that while the greatest 
miss rates are for small lesions, miss rates for large lesions are 
still significant.25 In addition to the holding back of mucosal 
folds, the EV also stabilises colonoscope position and can help 
prevent slippage back of the scope avoiding rapid slide by of 
areas of mucosa. This stabilisation could provide an explana-
tion for improved cancer detection; however, one would expect 
cancer detection to mirror detection of large polyps. Therefore, 
although the increase in cancer detection was significant and 
should not be ignored (with the authors unable to find another 
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Table 5 Secondary outcomes
Analysis SC n (%) EAC n (%) Difference (one-sided 97.5% CI) One-sided P value
Mean adenomas per procedure *
  Global 0.75 (1.40)   0.95 (1.89) 0.20 (0.07 to ∞) 0.02
  Non-BCSP 0.37 (0.80)   0.44 (1.24) 0.07 (−0.04 to ∞) 0.42
  BCSP 1.20 (1.77)   1.59 (2.32) 0.39 (0.15 to ∞) 0.004
Polyp detection rate
  Global 424 (48.0%) 480 (54.1%) 6.1% (2.2% to ∞) 0.005
  Non-BCSP 169 (35.1%) 189 (38.3%) 3.1% (−2.0% to ∞) 0.16
  BCSP 255 (63.3%) 291 (73.9%) 10.6% (5.2% to ∞) <0.001
Sessile serrated adenomas
  Global 10 (1.1%) 20 (2.3%) 1.1% (0.1% to ∞) 0.03
  Non-BCSP 5 (1.0%) 12 (2.4%) 1.4% (0.0% to ∞) 0.05
  BCSP 5 (1.2%) 8 (2.0%) 0.8% (−0.7% to ∞) 0.19
Left colon adenomas
  Global 196 (22.2%) 232 (26.1%) 4.0% (0.6% to ∞) 0.03
  Non-BCSP 64 (13.3%) 71 (14.4%) 1.1% (−2.6% to ∞) 0.31
  BCSP 132 (32.8%) 161 (40.9%) 8.1% (2.5% to ∞) 0.009
Right colon adenomas
  Global 219 (24.8%) 244 (27.5%) 2.7% (−0.7% to ∞) 0.10
  Non-BCSP 66 (13.7%) 74 (15.0%) 1.3% (−2.4% to ∞) 0.29
  BCSP 153 (38.0%) 170 (43.2%) 5.2% (−0.5% to ∞) 0.07
Large adenomas (10+ mm)
  Global 61 (6.9%) 70 (7.9%) 1.0% (−1.1% to ∞) 0.21
  Non-BCSP 11 (2.3%) 16 (3.2%) 1.0% (−0.8% to ∞) 0.18
  BCSP 50 (12.4%) 54 (13.7%) 1.3% (−2.6% to ∞) 0.29
Small adenomas (6–9 mm)
  Global 68 (7.7%) 94 (10.6%) 2.9% (0.6% to ∞) 0.02
  Non-BCSP 25 (5.2%) 19 (3.9%) −1.4% (−3.5% to ∞) 0.85
  BCSP 43 (10.7%) 75 (19.0%) 5.4% (4.2% to ∞) <0.001
Diminutive adenomas (≤5 mm)
  Global 272 (30.8%) 307 (34.6%) 3.8% (0.1% to ∞) 0.04
  Non-BCSP 92 (19.1%) 102 (20.7%) 1.5% (−2.7% to ∞) 0.28
  BCSP 180 (44.7%) 205 (52.0%) 7.4% (1.6% to ∞) 0.02
*Mean and SD reported.
BCSP, Bowel Cancer Screening Programme; EAC,  EV-assisted colonoscopy; SC,  standard colonoscopy. 
Table 6 Cancer detection rate
SC (n=884) EAC (n=888) % Difference (one-sided 95% CI) One-sided P value
All cancers 
  Global 20 (2.3%) 36 (4.1%) 1.8 % (0.4% to ∞) 0.02 
  Non-BCSP 5 (1.0%) 10 (2.0%) 1.0 % (−0.3% to ∞) 0.11
  BCSP 15 (3.7%) 26 (6.6%) 2.9 % (0.3% to ∞) 0.03
Endoscopically detected cancers 
  Global 19 (2.2%) 32 (3.6%) 1.5% (0.1% to ∞) 0.03 
  Non-BCSP 4 (0.8%) 9 (1.8%) 1.0 % (−0.2% to ∞) 0.09 
  BCSP 15 (3.7%) 23 (5.8%) 2.1 % (−0.3% to ∞) 0.08 
Polyp cancers 
  Global 1 (0.1%) 4 (0.5%) 0.3 % (−0.1% to ∞) 0.09 
  Non-BCSP 1 (0.2%) 1 (0.2%) 0.0 % (−0.5% to ∞) 0.51
  BCSP 0 (0.0%) 3 (0.8%) 0.8 % (0.0% to ∞) 0.04
BCSP, Bowel Cancer Screening Programme; EAC, EV-assisted colonoscopy; SC, standard colonoscopy.
explanation for this finding), the disparity between cancer and 
large polyp detection warrants cautious interpretation of the 
increased cancer detection. EV did increased the detection of 
SSPs; however, this was a small change and the overall detection 
rate of SSPs was low. Therefore, the clinical significance of this 
finding should not be overinterpreted.
The benefits of improving ADR on reducing PCCRC rates 
have been demonstrated in populations directly screened by 
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Table 7 Caecal intubation rate, insertion time and withdrawal time
SC EAC Difference (one-sided 97.5% CI) non-inferiority margin
Caecal intubation rate: N (%)
  Global 852 (96.4%) 858 (96.7%) 0.4% (−1.3% to ∞) 5%
  Non-BCSP 458 (95.2%) 474 (96.0%) 0.7% (−1.8% to ∞) 5%
  BCSP 394 (97.8%) 384 (97.7%) −0.1% (−2.1% to ∞) 5%
Insertion time: median (IQR)
  Global 9 (6, 15) 8 (5, 12) −1 (−∞ to 0) 1 min
  Non-BCSP 12 (8, 17) 10 (7, 14) −2 (−∞ to −1) 1 min
  BCSP 6 (4, 11) 7 (4, 10) 0 (−∞ to 1) 1 min
Withdrawal time*: median (IQR)
  Global 8 (6, 11) 8 (6, 10) 0 (−∞ to 0) 1 min
  Non-BCSP 7 (5, 10) 7 (5, 10) 0 (−∞ to 1) 1 min
  BCSP 9 (7, 12) 8 (6, 10) −1 (−∞ to 0) 1 min
*Figures for patients where no polyps were found only.
 BCSP, Bowel Cancer Screening Programme; EAC, EV-assisted colonoscopy; SC, standard colonoscopy. 
Table 8 Use of hyoscine-n-butylbromide, carbon dioxide gas, position change and rectal retroflexion
SC (n=884) EAC (n=888) % Difference (one-sided 97.5% CI) One-sided P value
Hyoscine-n-butylbromide use
  Global 568 (64.3%) 627 (70.6%) 6.4% (2.7% to ∞) 0.002
  Non-BCSP 259 (53.9%) 327 (66.2%) 12.3% (7.2% to ∞) <0.001
  BCSP 309 (76.7%) 300 (76.1%) −0.5% (−5.5% to ∞) 0.57
Carbon dioxide gas use
  Global 678 (76.7%) 672 (75.7%) −1.0% (−4.3% to ∞) 0.69
  Non-BCSP 311 (64.7%) 315 (63.8%) −0.9% (−5.9% to ∞) 0.61
  BCSP 367 (91.1%) 357 (90.6%) −0.5% (−3.8% to ∞) 0.59
Position change
  Global 772 (87.5%) 718 (81.3%) −6.2% (−9.0% to ∞) 1.00
  Non-BCSP 413 (86.0%) 392 (79.8%) −6.2% (− 10.2% to ∞) 0.99
  BCSP 359 (89.3%) 326 (83.2%) −6.1% (−10.2% to ∞) 0.99
Rectal retroflexion
  Global 785 (88.8%) 723 (81.4%) −7.4% (−10.1% to ∞) 1.00
  Non-BCSP 422 (87.7%) 401 (81.2%) −6.6% (−10.4% to ∞) 1.00
  BCSP 363 (90.1%) 322 (81.7%) −8.3% (−12.4% to ∞) 1.00
BCSP, Bowel Cancer Screening Programme; EAC, EV-assisted colonoscopy; SC, standard colonoscopy.
Table 9 Use of nitrous oxide and oxygen gas, intravenous sedation and intravenous analgesia
SC EAC Difference (one-sided 97.5% CI)
non-inferiority margin or one-
sided P value
Nitrous oxide and oxygen gas
  Global 291 (32.9%) 283 (31.9%) −1.0% (−∞ to 3.3%) 10%
  Non-BCSP 209 (43.5%) 180 (36.4%) −7.0% (−∞ to −0.9%) 10%
  BCSP 82 (20.4%) 103 (26.2%) 5.9% (−∞ to 11.7%) 10%
Intravenous sedation
  Global 591 (66.9%) 586 (66.1%) −0.8% (−∞ to 3.6%) 10%
  Non-BCSP 349 (72.6%) 357 (72.3%) −0.3% (−∞ to 5.3%) 10%
  BCSP 242 (60.1%) 229 (58.3%) −1.8% (−∞ to 5.0%) 10%
Intravenous analgesia
  Global 582 (65.8%) 588 (66.3%) 0.5% (−∞ to 4.9%) 10%
  Non-BCSP 342 (71.1%) 360 (72.9%) 1.8% (−∞ to 7.4%) 10%
  BCSP 240 (59.6%) 228 (58.0%) −1.5% (−∞ to −5.3%) 10%
BCSP, Bowel Cancer Screening Programme; EAC, EV-assisted colonoscopy; SC, standard colonoscopy.
colonoscopy. However, it is not possible to fully quantify the 
effect of a 10.8% rise in ADR in FOBt-positive BCSP patients as 
no data exist on long-term outcomes in this population. In addi-
tion, the ceiling at which further improvement in ADR confers 
no additional patient benefit has not been established. Neverthe-
less, an increase of 10.8% in ADR in a screening population is 
likely to be highly significant.
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Table 10 Patient risk group
Patient group risk SC n (%) EAC n (%) Two-sided P value
All patients No adenoma 564 (63.8%) 525 (59.1%) 0.03
Low 205 (23.2%) 225 (25.3%)
Intermediate 87 (9.8%) 95 (10.7%)
High 28 (3.2%) 43 (4.8%)
Non-BCSP No adenoma 366 (76.1%) 374 (75.7%) 0.78
Low 93 (19.3%) 89 (18.0%)
Intermediate 18 (3.7%) 25 (5.1%)
High 4 (0.8%) 6 (1.2%)
BCSP No adenoma 198 (49.1%) 151 (38.3%) 0.004
Low 112 (27.8%) 136 (34.5%)
Intermediate 69 (17.1%) 70 (17.8%)
High 24 (6.0%) 37 (9.4%)
BCSP, Bowel Cancer Screening Programme; EAC, EV-assisted colonoscopy; SC, standard colonoscopy.
ADR is the most widely used quality marker but the impor-
tance of MAP is growing as high-quality colonoscopy should find 
all adenomas in a patient, whereas where ADR is used a single 
adenoma positively affects this key performance indicator.16 
Parallel improvement in both ADR and MAP in this study add 
to its weight and suggest genuine clinical benefit associated with 
EV use. Withdrawal times were equivalent in both groups. The 
improved detection without prolongation of the procedure may 
reflect improved efficiency with EV conferred by stabilisation 
of the colonoscope tip and less need for backward and forward 
manoeuvring of the tip to see around folds. Insertion times were 
quicker with EV and this may be due to the ability of EV to 
stabilise the scope tip during scope straightening manoeuvres.
Earlier trials of the original Endocuff reported improvements 
in ADR of up to 14.7%,26 27 but results were not replicated in 
a large Dutch trial.16 Studies of the original Endocuff were also 
limited by the reporting of high rates of mucosal abrasions. EV 
differs from the original Endocuff in having only one row of 
projections that are softer and 2 mm longer. The single ring of 
softer projections appears to be more manoeuvrable and do 
not cause the same abrasions. Abrasions were not observed in 
this study. The results of the current trial are similar to those 
of pilot studies, which showed a 16% improvement in ADR in 
a screening setting.28 In contrast, a single-centre trial of EV has 
recently reported no improvement in ADR.29 This was, however, 
a smaller trial with numbers that may have been insufficient to 
demonstrate the results shown in the current trial. Additionally, 
this trial reported an extremely high ADR in the control arm 
and increasing that ADR with EV would have been very difficult.
Devices attached to colonoscopes should not hinder the 
procedure, increase discomfort or cause AEs. In addition, it is 
important that devices should not need to be removed often. 
EV did not hinder colonic intubation and intubation time was 
quicker when EV was used—an EV cuff removal rate of 4.1% 
is an acceptably low level. Colonic spasm may hinder insertion 
during any colonoscopy and this may be more of an issue when 
EV is used. Use of hyoscine-n-butylbromide was higher in the 
EAC arm and it is likely that colonoscopists were more likely 
to use antispasmodics to aid insertion. Hyoscine-n-butylbromide 
is used widely in BCSP as standard practice and this is likely to 
explain the lack of increase in use in this group.
EAC was non-inferior in almost all measures of patient experi-
ence with patients reporting no difference in experience overall 
when EV was used. When asked specifically regarding anal 
insertion, EAC was reported to be slightly more uncomfortable. 
Where colonoscopy is undertaken under deep sedation, this is 
not likely to be an issue but where light or no sedation is used, 
adequate cuff lubrication and gentle insertion technique should 
be optimised to minimise any anal discomfort. EV was safe and 
did not cause any AEs in this trial.
Many studies purporting to demonstrate benefits of new tech-
nologies are conducted in expert (often single) centres. This 
study was undertaken in a mixture of academic and community 
settings meaning that results are generalisable to standard clin-
ical practice. Other studies have reported adenoma miss rate 
or other markers of quality; however, ADR is the most widely 
used marker and has been shown to correlate strongly with 
PCCRC rates and therefore was chosen as the primary outcome 
measure. One limitation of this study is that despite being an 
RCT it could not be performed with operator blinding as the 
cuff is visible on insertion, the projections can be clearly seen 
holding back folds and indeed EV can only be used correctly if 
the endoscopists knows it is there. Tandem studies have previ-
ously been used to compare devices in colonoscopy to identify 
missed lesions. However, an RCT comparing ADR in two equiv-
alent arms allowing for confounders is the optimal way to study 
this intervention. As this study compared ADR in both arms and 
both arms involved a single colonoscopy, missed adenomas are 
unlikely to have a significant impact on results. Other measures 
known to improve ADR were comparable in the two groups.
EV provides a method of improving ADR that is simple, safe, 
well tolerated and at relatively low cost. EV improves detec-
tion of left-sided adenomas and has potential to benefit flexible 
sigmoidoscopy screening programme as well as those that focus on 
colonoscopy.30
COnCluSIOn
The ADENOMA study demonstrated that EV significantly 
improved ADR, MAP and cancer detection, most clearly notice-
able in FOBt-positive screening patients. EV facilitated quicker 
colonic intubation and was non-inferior in all aspects of patient 
comfort other than causing minimal discomfort on anal intuba-
tion. EV should be recommended for use in patients with high 
risk of having adenomas such as those undergoing colonoscopy 
following a positive FOBt.
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